BioVentrix Advances Its Revivent-TC Ventricular Enhancement Technology For Heart Failure

Heart failure (HF), the leading cause of hospitalization in Americans over age 65, is both progressive and progressing. Driven by the aging population and an increase in ischemic heart disease, hypertension, and diabetes, the number of Americans with HF is projected to climb 46% from five million in 2012 to eight million in 2030, according to the American Heart Association. What’s more, the direct and indirect costs of treatment are forecast to more than double from $31 billion to $70 billion in the same time period. Despite advances in pharmacological and device therapy over the years, the prognosis for patients with this disease has not been impacted significantly, and HF continues to loom as a new epidemic in cardiovascular medicine. Privately held, San Ramon, CA-based BioVentrix Inc. hopes to change this trajectory of patient outcomes with a unique, minimally invasive approach to treating patients who develop ischemic HF following a heart attack. It’s the Revivent-TC Ventricular Enhancement System, which employs titanium anchors to reshape the scarred and enlarged left ventricle of the heart and enhance myocardial pumping efficiency, and it is showing promise for those who have suffered a heart attack but are too sick to tolerate invasive heart surgery.

BioVentrix’s goal is to offer a treatment option for patients prior to them needing a ventricular assist device (VAD) that can get them out of the hospital faster than with...